Potency of levothyroxine products.
Potency of levothyroxine products.
复制标题
左旋甲状腺素产品的效力。
DOI：
--
复制
发表时间：
1984
期刊：
影响因子：
--
通讯作者：
W. Szpunar
中科院分区：
文献类型：
--
作者：
S. Stoffer;W. Szpunar
最近，生产我们在实践中最常使用的左旋甲状腺素产品的公司改用高压液相色谱法（HPLC）来监测他们的产品。因此，该品牌产品现在含有100%的预期效力，在我们的实验室通过放射免疫测定法测定。我们实验室先前的研究表明，该产品仅具有预期效力的78%。今年，我们的患者平均血清游离甲状腺素指数（FTI）高于过去。此外，今年有更多的血清FTI水平升高，血清促甲状腺激素水平升高较少。医生应该注意到，随着更多的公司改用HPLC法，左甲状腺素产品的生产商在未来一年左右可能会做出产品变更。在此过渡期内，应仔细监测接受左旋甲状腺素产品的患者的甲状腺功能研究。我们怀疑新产品将更加一致，并具有更可靠的保质期。
Recently, the company that manufactures the levothyroxine product that we use most often in our practice switched to high-pressure liquid chromotography (HPLC) to monitor their product. As a result, the brand name product now contains 100% of expected potency as determined in our laboratory by radioimmunoassay. Previous studies in our laboratory demonstrated that this product had only 78% of expected potency. This year our patients have a higher mean serum free thyroxine index (FTI) than they have had in the past. In addition, there were more elevated serum FTI levels and fewer elevated serum thyroid-stimulating hormone levels this year. Physicians should be aware of possible product changes being made by manufacturers of levothyroxine products over the next year or so as more companies switch to the HPLC method. The thyroid function studies of patients receiving levothyroxine products should be rather carefully monitored during this transitional period. We suspect that the new products will be more consistent and have a more reliable shelf life.